Clinical Trial Update: Everolimus and LongActing Octreotide Trial in Polycystic Livers [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of everolimus and long-acting octreotide for polycystic liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Liver Disease

Drugs mentioned

• Everolimus (Afinitor) (everolimus)
• Octreotide long-acting release (Sandostatin LAR) (octreotide)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Polycystic Liver Disease | Phase 2 | Status: COMPLETED